

## Supporting Information

### **Photothermal self-adjutant porous microneedles for self-healing encapsulation and sustained release of antigens to improve adaptive immunity**


Xin Wang <sup>a,b</sup>, Zhiming Li <sup>b</sup>, Jiahui Fu <sup>a,b</sup>, Xueyu Wen <sup>b</sup>, Zhenni Chen <sup>b</sup>, Shaohua Li <sup>b</sup>, Tianqi Liu <sup>b,\*</sup>,  
Fei Jia <sup>b,\*</sup>, Hao Chang <sup>b,\*</sup>

<sup>a</sup> College of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, China.


<sup>b</sup> Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China

\*Corresponding author


Email: liutianqi@him.cas.cn (T.Q. Liu), jiafei@him.cas.cn (F. Jia), changhao@him.cas.cn (H. Chang).




**Figure S1.** Morphological development of H-PSAPMNs during fabrication. (A) Representative microscopy of MNs after cryo-demoulding, phase-separation, self-healing, and separation. Scale bar: 250  $\mu\text{m}$ . (B) Statistical analysis of the heights of cryogenically demolded MNs, PSAPMNs, H-PSAPMNs, and the supportive cap. Data are presented as mean  $\pm$  s.d. ( $n = 10$ ).  $p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ,  $****p < 0.0001$ , ns = no significant difference.




**Figure S2.** Self-healing behavior of PSAPMNs. High-magnification cross-sectional SEM images of PMNs and PSAPMNs subjected to NIR irradiation ( $0.6 \text{ W/cm}^2$ ) for varying durations. Scale bars:  $20 \mu\text{m}$ .




**Figure S3.** Structural integrity of OVA. Circular dichroism (CD) spectra of native OVA (black line) and OVA recovered from H-PSAPMNs after heating treatment at 45 °C for 90 minutes (red dashed line).




**Figure S4.** Antigen sealing performance. Representative bright-field and fluorescence microscopy images of PSAPMNs and H-PSAPMNs (both loaded with FITC-OVA) after immersion in a water bath. Scale bar: 1000  $\mu\text{m}$ .




**Figure S5.** (A) Force-displacement curve for H-PSAPMNs and H-PSAPMNs loaded with OVA. (B) Compressive strength of H-PSAPMNs and H-PSAPMNs loaded with OVA. Data are presented as mean  $\pm$  s.d. ( $n = 4$ ). ns = no significant difference.




**Figure S6.** Reactive oxygen species (ROS) generation in mouse skin following various treatments. (A) Representative fluorescence microscopy images showing ROS levels in skin tissues from four groups: untreated control, H-PSAPMNs, NIR irradiation (10 min), and H-PSAPMNs combined with NIR irradiation (10 min). Scale bar: 500  $\mu$ m. (B) Quantitative analysis of relative ROS levels among the treatment groups. Data are presented as mean  $\pm$  s.d. (n = 4). \*\*\*\*P < 0.0001.




**Figure S7.** Histological evaluation of skin safety after photothermal treatment. Representative H&E-stained sections of skin tissues collected 24 hours post-treatment from the untreated group and the H-PSAPMNs + NIR group. Scale bar: 200  $\mu\text{m}$ .




**Figure S8.** Evaluation of HSP90 expression in skin tissues. (A) Representative immunofluorescence images of skin sections stained for HSP90 (green) and nuclei (blue) from the untreated, H-PSAPMNs, and H-PSAPMNs+NIR groups. Scale bar = 200  $\mu$ m. (B) Quantitative analysis of HSP90 levels in skin tissue homogenates measured by ELISA. Data are presented as mean  $\pm$  s.d. (n = 3). \*\*\*\*p < 0.0001, ns = no significant difference.




**Figure S9.** Representative flow cytometry plots illustrating the percentages of CD80<sup>+</sup>CD86<sup>+</sup> DCs, CD8<sup>+</sup>CD3<sup>+</sup> T cells, CD4<sup>+</sup>CD3<sup>+</sup> T cells, CD8<sup>+</sup>CD69<sup>+</sup> T cells, and CD4<sup>+</sup>CD69<sup>+</sup> T cells in draining lymph nodes (dLNs) isolated from mice across different vaccination groups.




**Figure S10.** Flow cytometry gating strategy for immune cells in draining lymph nodes. Total lymphocytes were first gated based on the FSC-A and SSC-A, and single cells were gated based on FSC-A and FSC-H. Data were analyzed using FlowJo software, and expressed as a percent of (A) CD80<sup>+</sup>CD86<sup>+</sup> DCs. (B) CD3<sup>+</sup>CD4<sup>+</sup> T cells and CD3<sup>+</sup>CD8<sup>+</sup> T cells. (C) CD69<sup>+</sup>CD4<sup>+</sup> T cells and CD69<sup>+</sup>CD8<sup>+</sup> T cells.



**Figure S11.** Representative flow cytometry plots illustrating the percentages of CD3<sup>+</sup>CD8<sup>+</sup> T cells, CD8<sup>+</sup>CD69<sup>+</sup> T cells, and CD8<sup>+</sup> memory T cells in spleen isolated from mice across different vaccination groups.



**Figure S12.** Representative flow cytometry plots illustrating the percentages of CD3<sup>+</sup>CD4<sup>+</sup> T cells, CD4<sup>+</sup>CD69<sup>+</sup> T cells, and CD4<sup>+</sup> memory T cells in spleen isolated from mice across different vaccination groups.



**Figure S13.** Flow cytometry gating strategy for immune cells in the spleen. Total lymphocytes were first gated based on FSC-A and SSC-A, and single cells were gated based on FSC-A and FSC-H. Data were analyzed using FlowJo software and are expressed as a percent of: (A) CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T cells. (B) CD69<sup>+</sup>CD4<sup>+</sup> and CD69<sup>+</sup>CD8<sup>+</sup> T cells. (C) CD44<sup>+</sup> and CD62L<sup>+</sup> memory T cells.